STTR Phase I: Self-assembling molecular brachytherapy for treatment of metastatic cancer

STTR 第一期：自组装分子近距离放射治疗用于治疗转移性癌症

• 批准号: 2136700
• 负责人: Nicholas Trotta
• 金额: $ 25.57万
• 依托单位: Oncurie, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136700&HistoricalAwards=false
• 关键词: STTR; Phase; Self; assembling; molecular

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to enable radiotherapies for metastatic cancer, estimated to account for 90% of the 600,000 cancer deaths in the US each year. Of the approximately 1.8 million new cancer cases diagnosed each year in the US, nearly half are candidates for improved outcomes using some form of radiation-based therapy. Metastatic cancer, however, is generally not treated with radiotherapies due to the need for prior knowledge of the metastatic sites. The proposed project treats metastatic cancer by using the cancer cells themselves to help deliver the radiation. This technology may generate reliable efficacy of radiotherapy for the treatment of the most lethal forms of cancer.This Small Business Innovation Research Phase I project seeks to advance radiotherapy that exploits cancer cells themselves as catalysts for therapeutic delivery. After systemic administration or local injection, the monomers are expected to diffuse through tissues and subsequently polymerize, immobilizing radionuclides in the extracellular space of cancer cells. Non-cancerous cells will be minimally impacted, as soluble monomers will remain subject to diffusion and relatively rapid tissue clearance in the absence of cancer cell-derived catalysts. The chemistry at the core of the approach is an enzyme-triggered polymerization of native-like compounds under physiological conditions. The final therapeutic compound features the polymerizable compound and covalently-conjugated radionuclide 131-I, a commonly used radiotherapy isotope.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的更广泛的影响/商业潜力是使转移性癌症的放射性疗法能够占美国每年60万癌症死亡中的90％。在美国每年诊断出的大约180万个新的癌症病例中，使用某种形式的基于辐射的治疗，将近一半是改善结局的候选人。然而，由于需要先验转移部位的知识，转移性癌通常不接受放射性疗法治疗。拟议的项目通过使用癌细胞本身来治疗转移性癌症来帮助提供辐射。这项技术可能会产生放射疗法的可靠疗效，以治疗最致命的癌症。这一小型企业创新研究阶段I项目旨在提高放射疗法，从而利用癌细胞本身作为治疗递送的催化剂。全身给药或局部注射后，预计单体将通过组织扩散，然后在癌细胞的细胞外空间中固定放射性核素。 由于没有癌细胞衍生的催化剂，可溶性单体将继续受到扩散和相对较快的组织清除，因此非癌细胞将受到最小的影响。该方法核心的化学因素是生理条件下类似天然的化合物的酶触发的聚合。 最终的治疗化合物具有可聚合的化合物和共价偶联的放射性核素131-I，这是一种常用的放疗同位素。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子优点和更广泛的影响审查的评估来通过评估来支持的。